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Abstract
Atherosclerosis is a inflammatory-immunological-degenerative process. Cardiovascular diseases account for 
42% of premature deaths among men and 52% of premature deaths among woman. Identification of classical 
biomarkers of atherosclerosis, such as LDL, HDL and triglycerides may not be helpful in patients with moderate 
or unusual cardiovascular risk. Non-classical indicators of atherosclerosis include markers of the inflammatory 
process, markers of atherosclerotic plaque injury, acute phase proteins, ischemic markers, markers of tissue 
necrosis, markers of myocardial dysfunction. The identification of CVD biomarkers enables the classification of 
patients to appropriate cardiovascular risk groups. Knowledge about the CVD risk group makes it possible to 
take rapid therapeutic intervention aimed at limiting this risk. Pharmacotherapy for cardiovascular diseases is 
primarily based on lowering cholesterol’s level in the blood. Additional properties of statins (the most important 
lipid-lowering drugs) enable their pleiotropic effect by limiting the progression of atherosclerotic lesions by re-
ducing the volume of atherosclerotic plaque. Further research on the pathogenesis of atherosclerosis will allow 
learning new risk factors and new biomarkers of this disease.
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Introduction
Atherosclerosis is a inflammatory-immunological-de-
generative process involving small and medium-caliber 
arteries, which is responsible for the majority of CVD 
(cardiovascular diseases) [1]. Atherosclerotic lesions 
arise in childhood and even in fetal life [2]. Cardiovas-
cular diseases account for 42% of premature deaths 
among men and 52% of premature deaths among wo-
man [3]. Cardiovascular diseases are the most common 
cause of death in Poland. According to GUS (Central 
Statistical Office) data, in 2014 these diseases accounted 
for > 48% of premature deaths of Poles. Atheroscle-
rosis is also responsible for peripheral arterial diseases 
(PAD), and what is more, it is the most important cause 
of amputation of legs [4]. Risk factors of progression of 
atherosclerotic lesions are divided into modifiable and 
unmodifiable, as well as, classical and non-classical [5] 
(Fig. 1). According to the National Health Service 
(NHS), the biggest life threats in developed countries 
are hypertension, smoking, hypercholesterolemia, obe-
sity, dietary mistakes, lack of physical activity, excessive 
alcohol consumption, infections, non-traffic accidents, 
traffic accidents, illegal drug use, murders, medical 
complications, war, pregnancy and childbirth. The prev-
alence of the most important risk factors for cardiovas-
cular disease in Poland was examined in the NATPOL 
2011 Study (Fig. 2.). The most important cause of 
premature deaths in the world is hypertension [6]. The 
Cardiovascular Disease Prevention and Treatment Pro-
gram (POLKARD 2017–2020), which aims to combat 
the classic risk factors for atherosclerosis, introduce 
modern effective diagnostic and therapeutic methods 
and act to level out disproportions arising in the country 
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in accessing highly specialized health services in the field 
of cardiology, pediatric cardiology, cardiac surgery and 
neurology. Early detection of atherosclerotic lesions 
enables the introduction of appropriate prophylaxis 
aimed at reducing cardiovascular risk. Biomarkers 
can be used in the early detection of atherosclerosis. 
The main risk factors (classical risk factors) for CVD 
affecting cardiovascular risk are SBP (systolic blood 
pressure), total cholesterol, age, sex and smoking [5]. 
Cardiovascular risk can be presented as a risk of death 
(European systems: Euro-SCORE, Pol-SCORE) or as 
a risk of a cardiovascular event (American systems, 
for example, Framingham Risk Score). The influence 
of classical CVD risk factors on the incidence of CVD 
is shown in fig. 3. It is also worth remembering about 
other risk factors for CVD. An important risk factor of 
CVD is also diet. It has been reported that oxysterols 
increase inflammation, lipid markers levels and reflect 
accelerated endothelial dysfunction [7]. The number 
of CVD risk factors does not always correlate with the 
actual cardiovascular risk. In 1/5 of patients with diag-
nosed coronary artery disease, no classic risk factors 
are found, while 40% have only one risk factor [8, 9]. 
Pathogenesis of atherosclerosis
Atherosclerosis is a chronic disease with a multifactorial 
pathogenesis. It mainly concerns the aorta, coronary 
vessels, and in particular the branching of these vessels. 
Atherosclerotic lesions localize in the tunica intima and 
tunica media of vascular wall. The location of atheroscle-
rotic lesions varies between men and women. Among 
women, atherosclerotic lesions are located in the 
carotid arteries — 24.1%; coronary arteries — 4.5%; 
abdominal aorta — 22.8% and ilio-lumbar arteries — 
30.1%. Among men, the incidence of atherosclerosis in 
the above locations is as follows: 36.9%; 26.1%; 27.2% 
and 54.1% [10]. Atherosclerosis can be generalized — 
including > 3 vascular bearings; indirect — including 
2-3 vascular bearings and local — including 1 vascular 
bearing [10]. Atherosclerosis gradually narrows the 
lumen of the vessel, which reduces the flow of blood to 
the tissues, leading to their ischemia. The scientific be-
ginnings of research on atherosclerosis date back to the 
second half of the 19th century. In 1856 Rudolf Virchow 
showed that atherosclerotic lesions are composed of 
large amounts of lipid components (cholesterol and 
triglycerides). Another researcher dealing with ather-
Classical risk factors
Unmodifiable risk factors
• Male sex
• Age > 55 in men
   and > 65 in woman
• Heart and vascular diseses in the family
• Smoking
• Low physical activity
• Unhealthy eating habits
• Overweight and obesity
• Arterial hypertension
• Hypercholesterolaemia
• Diabetes
• Kidney diseases
• Obstructive sleep apnea
• Sexual dysfunction
• Depression and anxiety disorders
• Air pollution
• Periodontal disease
• Hyperhomocysteinemia
• Other — psoriasis, fungal infections
Modifiable risk factors
Non-classical risk factors
Figure 1. Risk factors for cardiovascular diseases [based on 5]
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Figure 2. Prevalence of risk factors for cardiovascular diseases 
in Poland among patients aged 18–79 according to the results 
of the NATPOL 2011 Study
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osclerosis was Nikolai Aniczkov. In 1913, he showed 
that the use of a cholesterol-rich diet in a rabbit for 
a dozen or so weeks leads to atherosclerotic lesions. In 
1874, Joseph Goldstein and Michael Brown described 
the mechanism of cholesterol uptake by the cells at the 
participation by the apoB100/apoE receptor. Another im-
portant event in the history of atherosclerosis research 
was Russell Ross’s demonstration that the key to ather-
osclerosis is the interaction of monocytes/macrophages 
with vascular endothelium (modified theory of uniform 
response to injury). Macrophages under the vascular en-
dothelium remove cholesterol, transforming into foam 
cells. Foam cells produce, among others, extracellular 
matrix metalloproteinases (MMPs) that damage the 
vascular endothelium [11]. Atherosclerotic lesions are 
classified according to AHA (American Heart Associa-
tion) recommendations [12]. There are three types of 
atherosclerotic lesions that constitute the early phase 
of the atherosclerotic process. Type I is characterized 
by the presence of cholesterol-containing foam cells. 
The II type is characterized by an increase in the num-
ber of foam cells and the appearance of pathologically 
altered smooth muscle cells. Type III is characterized 
by extracellular lipid accumulation and the onset of 
fibrosis. Atherosclerotic changes begin in early child-
hood and even fetal life. It should be mentioned that 
the stages I–III are reversible [13]. Further accumulation 
of lipids in the vascular wall leads to the formation of 
atherosclerotic plaques. Lipids constitute 10–70% of 
the volume of atherosclerotic plaque. The construction 
of atherosclerotic plaque can be varied. In type IV, the 
surrounding enamel-sheath core consists only of the 
inner membrane. In type V, the atherosclerotic plaque 
is surrounded by collagen and smooth muscle cells. In 
addition, type V is divided into subtypes. The Va sub-
type is characterized by a pronounced lipid core, the 
Vb subtype is characterized by calcifications, while the 
Vc subtype is characterized by a lack of the core and 
a large amount of connective tissue. Atherosclerotic 
plaques type IV and V were found in 20% of men aged 
30–34 [14]. Type VI is an unstable atherosclerotic plaque 
(damage of inner membrane) or atherosclerotic plaque 
that has burst. Types V and VI atherosclerotic plaque 
are irreversible [15]. Gradually enlarging atheroscle-
rotic plaque does not cause clinical symptoms until 
the narrowing of light does not exceed 70–80% of 
the diameter of the vessel, which significantly reduces 
blood flow, eg to the myocardium — a stable example 
of angina pectoris. In contrast, atherosclerotic plaque 
rupture, most often at less than 50% of the vessel lu-
men, is responsible for rapidly occurring symptoms such 
as acute coronary syndrome or stroke [16]. In 79.5% of 
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Figure 3. Morbidity of ischemic heart disease depending on the number of cigarettes smoked, serum cholesterol, level of systolic 
blood pressure and the number of risk factors — Framingham Heart Study
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patients with coronary artery disease, PAD is diagnosed. 
Among patients with PAD, atherosclerosis occurred 
in 52.2%, while atherosclerosis of the lower limbs in 
68.5% of them [17]. The severity of the progression of 
atherosclerotic lesions depends on the number of risk 
factors. With age, thickening of the inner membrane 
occurs, which is caused by forces acting on the vessel 
(mainly shear stress). The dishes become thicker and 
have a higher average. Thickening of the inner mem-
brane promotes the loss of vascular endothelial cell 
integrity which leads to increased migration of LDL 
and monocyte lipoproteins into the inner wall layer 
of the vessel. The accumulation of lipids and cells of 
the immune system in the vascular wall promotes the 
development of atherosclerosis [18, 19]. 
Biomarkers of atherosclerosis
Identification of classical biomarkers of atherosclerosis, 
such as LDL (low-density lipoprotein), HDL (high-den-
sity lipoproteins), and triglycerides may not be helpful 
in patients with moderate or unusual cardiovascular 
risk. For more accurate management, non-classical 
atherosclerosis biomarkers may be helpful in these 
patient groups. Biomarker (indicator) of high clinical 
value should be characterized by high sensitivity, high 
repeatability of results and the possibility of application 
in clinical practice (low cost of laboratory mark) [7]. 
Biomarkers of atherosclerosis are characteristic of its 
particular stages. These include markers of the inflam-
matory process, markers of atherosclerotic plaque inju-
ry, acute phase proteins, ischemic markers, markers of 
tissue necrosis and markers of myocardial dysfunction. 
Biomarkers of the inflammatory proces
Interleukin 6 (IL-6)
One of the most important and most multi-functional 
interleukins. Together with TNF-a (tumour necrosis 
factor a), it belongs to pro-inflammatory cytokines. IL-6 
is mainly produced by monocytes and macrophages. 
IL-6 levels increase with age and are associated with 
increased mortality in nondisabled persons over age 
65 from both cardiovascular and non-cardiovascular 
events [20]. IL-6 is elevated in coronary heart disease 
patients and may be a biomarker of inflammation related 
to cardiovascular risk. IL-6 is involved in the formation 
of atherosclerotic plaques [21–23]. 
Myeloperoxidase (MPO)
Myeloperoxidase is a biomarker of both the inflamma-
tory process and the destabilization of atherosclerotic 
plaque. MPO is produced by neutrophils and mac-
rophages. Participates in the antimicrobial and antiviral 
reactions through the production of hypochlorous acid 
(HOCl). Myeloperoxidase also participates in the oxi-
dation of LDL lipoproteins (oxLDL). Oxidized LDL are 
highly atherogenic. Higher MPO activity in the blood of 
patients with ischemic heart disease was demonstrated 
in comparison to healthy people. In addition, plasma 
MPO levels have been shown to be higher in patients 
with acute coronary syndrome [24]. 
Tumour necrosis factor a (TNF-a)
Tumour necrosis factor a is the most important cyto-
kine that mediates effector pathways in both inflam-
matory disease target tissues and in atherosclerotic 
vessels. In addition, TNF-a is involved in the formation 
and enlargement of atherosclerotic plaques. TNF is an 
inhibitor of eNOS (endothelial nitric oxide synthase), 
increases the production of reactive oxygen species 
and reduces the effect of EDHF (endothelium-derived 
hyperpolarizing factor). These mechanisms lead to im-
pairment of vasodilatation and damage to the vascular 
endothelium due to the severity of inflammation [25]. 
Is a biomarker of increased cardiovascular risk [26]. It 
has been shown that the concentration of TNF-a in the 
blood increases with age. Elderly people who had higher 
levels of TNF-a in the blood more often had clinically 
diagnosed atherosclerosis [27]. 
Matrix metalloproteinase 9 (MMP-9)
Metalloproteinases are a very large family of calci-
um-dependent, zinc-containing endopeptidases. MMP-9 
is associated with inflammation and destabilization of 
atherosclerotic plaque. MMP-9 increases the infiltra-
tion of monocytes under the vascular endothelium. In 
addition, there is a positive correlation between the 
concentration of MMP-9 in the blood and the size of 
the lipid core and the risk of atherosclerotic plaque 
rupture [28]. Patients with unstable angina and NSTEMI 
(non-ST-elevation myocardial infarction) have increased 
levels of MMP-9 in the blood [29]. A positive correlation 
was found between the increased concentration of 
MMP-9 in the blood and the occurrence of myocardial 
infarction or stroke. However, it was not found that the 
elevated concentration of this metalloproteinase was 
a strong and independent cardiovascular risk factor [30]. 
Intercellular adhesion molecule 1 (ICAM-1; 
CD54) and vascular cell adhesion protein 1 
(VCAM-1; CD106)
The most important for the development of atheroscle-
rosis are ICAM-1 and VCAM-1. The presence of these 
adhesive molecules has been demonstrated in vessels 
predisposed to the development of atherosclerosis and 
within existing atherosclerotic lesions [31]. The ligand 
for ICAM-1 is LFA-1 (lymphocyte function-associated 
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antigen 1), which occurs on all types of leukocytes. The 
ligand for VCAM-1 is VLA-4 (very late antigen-4), found 
on monocytes and lymphocytes. Adhesion molecules 
are involved in the first stage of leukocyte penetration 
into the vascular endothelium - rolling. The interaction 
between ICAM-1 and LFA-1 and VCAM-1 and VLA-4 
is supported by PECAM-1 (platelet endothelial cell 
adhesion molecule 1). PECAM-1 is located on the 
surface of vascular endothelial cells at sites affected by 
the inflammatory process, therefore the migration of 
leukocytes under the vascular endothelium is intensified 
in the vascular regions where the process of inflam-
mation occurs [32]. Increased expression of ICAM-1 
and VCAM-1 has been shown to be an indicator of 
subclinical atherosclerosis [33]. 
C-reactive protein (CRP)
C-reactive protein is an acute phase marker. CRP is 
a biomarker of inflammation and destabilization of 
atherosclerotic plaque. CRP is produced mainly in 
hepatocytes as a result of IL-6 stimulation. It belongs 
to the pentraxin family. It can be used for the early 
identification of high cardiovascular risk patients. The 
FDA (Food and Drug Administration) recommends 
the determination of CRP concentration in the blood 
using the high sensitivity method (hsCRP, high-sensivity 
CRP). An increase in CRP concentration in blood above 
10 mg/l indicates an inflammatory proces [34]. The 
increase in CRP in the blood leads to: activation of the 
complement system, LDL oxidation, increased LDL 
to macrophages, reduction of NO (nitric oxide) pro-
duction, stimulation of TF (tissue factor) secretion by 
macrophages, increase in the concentration of adhesion 
molecules, increase of blood clotting due to the increase 
of PAI gene expression -1 (plasminogen activator inhibi-
tor-1). CRP also stimulates the production of IL-12 and 
INFg (interferon g) [34]. CRP is an important indicator 
of the risk of acute coronary syndrome without ST 
segment elevation [35]. 
Growth/differentiation factor 15 (GDF15)
Growth factor produced by macrophages, cardio-
myocytes and endothelial cells in response to the 
inflammatory process. It can be a potential biomarker 
in the stratification of cardiovascular risk. The GDF-15 
concentration below 1200 ng/l corresponds to the low 
cardiovascular risk (upper limit of reference values for 
healthy people), 1200-1800 ng/l — moderate (average) 
CVD risk, and exceeding 1800 ng/l — high CVD risk [36]. 
The increase in GDF-15 levels is accompanied by ath-
erosclerosis, atrial fibrillation, heart failure, pulmonary 
embolism, acute inflammation, renal failure and also 
some cancers [37]. The increased concentration of 
GDF-15 in response to inflammation aims to reduce 
the inflammation in the myocardium, its pathological 
remodelling and apoptosis of cardiomyocytes [38]. 
Fibrinogen
Fibrinogen is an acute-phase protein produced by the 
liver. It can be used to assess cardiovascular risk in 
patients with atypical cardiovascular profile [39]. It has 
been shown that fibrinogen concentration is higher in 
people with cardiovascular system diseases compared 
to healthy people. In addition, it has been found that 
determining fibrinogen levels in the blood may be useful 
in assessing the risk of thrombosis. Fibrinogen increases 
plasma viscosity, increases blood coagulation (through 
increased fibrin and increased aggregation of platelets), 
increases inflammation [40]. 
Uric acid
Uric acid is the final metabolite of purine bases. Numer-
ous epidemiological studies have shown that increased 
uric acid levels in the blood are an independent risk 
factor for cardiovascular disease [41]. Other studies 
suggest that hyperuricemia is not a risk factor of CVD 
but is a complication of CVD (obesity, the use of diu-
retics, hypertension, insulin resistance) [42]. Further 
clinical trials are needed to assess the clinical usefulness 
of the determination of uric acid levels in the blood.
Lipoprotein (a) — Lp (a)
Lipoprotein (a) is a modified LDL lipoprotein by at-
taching a specific apolipoprotein (a) to apoB100 [43]. 
Increased plasma Lp (a) is a genetically determined, 
independent, causative risk factor for cardiovascular 
disease. The physiological functions of Lp (a) include 
wound healing, promoting tissue repair and vascular 
remodelling. Like other lipoproteins, Lp (a) is also sus-
ceptible to oxidative changes, leading to extensive for-
mation of proinflammatory and proatherogenic oxidized 
phospholipids, oxysterols, oxidized lipid-protein adducts 
in Lp (a) molecules that consolidate the progression of 
atherosclerotic lesions and intimal thickening by induc-
tion of M1 macrophages, inflammation, autoimmunity 
and apoptosis [44]. In a prospective cohort study by 
Zhang et al. showed that elevated plasma Lp (a) con-
centration was a factor increasing the risk of stroke in 
adult Chinese [45]. Sadkowska et al. [46] on a group of 
142 men conducted a study to determine the usefulness 
of measuring Lp (a) and homocysteine in plasma. The 
subjects were divided into 4 groups depending on the 
number of pathological changes in the coronary vessels. 
Both Lp (a) and homocysteine have been shown to be 
elevated in patients with coronary artery disease. In their 
conclusions, the authors state that routine determination 
of homocysteine in patients with signs of coronary heart 
disease and determination of lipoprotein (a) in people 
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with a positive family history of cardiac disease may be 
diagnostically and clinically useful.
Biomarkers of destabilization  
of atherosclerotic plaque
Oxidized low-density lipoprotein — (oxLDL) and 
anti oxidized low-density lipoprotein antibody — 
anti oxLDL antibody
Oxidized low-density lipoprotein (oxLDL) is of key 
importance in the pathogenesis of atherosclerosis and 
the pathophysiology of major cardiovascular and brain 
events [47]. The oxLDL molecule acts as an antigen 
leading to the production of anti oxLDL antibodies [48]. 
Autopsy studies have shown that increased levels of 
oxLDL increase the risk of atherosclerotic plaque rup-
ture [49]. In addition, many studies have shown that an 
increase in blood oxLDL levels positively correlates with 
the risk of developing coronary artery disease and wors-
ens the prognosis in such patients [50]. LDL oxidation 
can affect different components of its molecule, which 
is why different anti-oxLDL antibodies can be formed. 
IgM anti-oxLDL antibodies have been shown to reduce 
the risk of severe coronary artery disease. In the case of 
IgG anti-oxLDL class, this compound is more complex 
and requires further research [50].
Soluble CD40 ligand (sCD40L)
Protein — CD40 receptor-ligand. It is mainly produced 
by cells of the immune system, vascular endothelial 
cells, vascular walls and epithelium. The CD40 recep-
tor is found on B lymphocytes, macrophages, vascular 
endothelial cells and myocytes. Separation of sCD40L 
leads to the production of MMPs and destabilization of 
the atherosclerotic plaque. Increased sCD40L concen-
tration was demonstrated in patients with myocardial 
infarction and unstable ischemic heart disease [51]. 
OPUS-TIMI16 Study showed higher blood sCD40L 
concentration compared to the control group (0.78 µg/l 
versus 0.52 µg/l) [52]. In addition, it has been shown 
that increased sCD40L concentration in the blood oc-
curs in patients with psoriasis [53]. The role of a CVD 
biomarker is unclear [7].
Placental growth factor (PIGF)
PIGF is a growth factor that belongs to the family of EGF 
(endothelial growth factor). It plays an important role 
in the pathogenesis of atherosclerosis by stimulating 
angiogenesis and increasing the migration of monocytes 
and macrophages into the vascular endothelium. As 
a biomarker, it can be important in assessing cardiovas-
cular risk among overweight children, obesity or met-
abolic syndrome. It has been shown that children with 
excessively increased body weight and with the met-
abolic syndrome have higher PIGF levels in the blood 
compared to healthy children. In addition, a positive 
correlation was found between PIGF concentration in 
the blood and troponin concentration in the blood [54].
Pregnancy-associated plasma protein A;  
pappalysin 1 (PAPP-A)
The protein produced by the placenta. It is a metal-
loproteinase. Probably PAPP-A is involved in the de-
struction of the fibrous cap of the plaque leading to its 
destabilization. Increased levels of PAPP-A have been 
demonstrated in patients with myocardial infarction, 
unstable ischemic heart disease and in patients who 
died suddenly due to CVD [55]. The CAPTURE Study 
showed that the increase in blood levels of PAPP-A 
in patients with acute coronary syndromes is of un-
favourable prognostic importance. As of today, there 
are technical problems in the performance of PAPP-A 
assays, because it occurs in the heterotetrameric form 
(in pregnant women) and homodimeric (in patients with 
acute coronary syndromes). PAPP-A may be used as a 
marker of death risk in acute coronary syndromes and 
identification of atherosclerotic plaques susceptible to 
rupture [56].
MicroRNA (miRNA)
MicroRNAs are short segments of RNA containing 
18–25 nucleotides. They arise in the process of tran-
scription of intron (non-coding) sequences and exon 
(encoding) sequences. Probably the expression of 1/3 
of human genes is regulated by miRNA. miRNAs are 
involved in the pathogenesis of many diseases [57]. 
Selected miRNAs involved in the development of the 
atherosclerotic process are presented in the Table 1.
The biomarkers of athersclerotic plaque  
destabilization also include the previously  
described MPO, MMP-9 and CRP
Interestingly, an increase in atherosclerotic destabiliza-
tion has been observed in patients with active ankylosing 
spondylitis. Increased blood levels of sCD40L and PIGF 
were observed in these patients. Importantly, these 
patients were not burdened with classic cardiovascular 
risk factors [59]. Whole-body cryotherapy decreases 
the levels of Inflammatory, oxidative stress, and ather-
osclerosis plaque markers in male patients with active 
phase ankylosing spondylitis in the absence of classical 
cardiovascular risk factors [60]. Chronic inflammatory 
state in these patients cause increased cardiovascular 
and cerebrovascular mortality [61]. 
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Biomarkers of thrombocyte activation
Lipoprotein-associated phospholipase A2  
(Lp-PLA2) and secretory phospholipase A2 
(sPLA2)
Lp-PLA2 is a protein also known as platelet-activating 
factor acetylhydrolase (PAF-AH). It is mainly produced 
by monocytes and macrophages. Lp-PLA2 has pro-in-
flammatory and atherogenic effects. Takes part in the 
oxidation of LDL lipoproteins. Increased Lp-PLA2 has 
been shown to increase cardiovascular risk. Inhibition 
of Lp-PLA2 (by the Darapladib) has a positive effect 
on the risk of CVD, therefore Lp-PLA2 may become 
a future target for pharmacotherapy [62]. sPLA2 is the 
phospholipase A2 isozyme. It is produced by inflamma-
tion cells in the atherosclerotic plaque and by ischemic 
cardiomyocytes. The relationship between sPLA2 
concentration and CVD risk was demonstrated [63].
The biomarkers of thrombocyte activation are also 
described sCD40L.
Biomarkers of neurohormonal activation
Copeptin
Copeptin is the C-terminal peptide of pre-provaso-
pressin. It is produced by brain cells. After transport 
from the hypothalamus to the pituitary gland and 
pre-provasopressin cleavage, the copeptin is released 
into the circulation in stoichiometric amounts along with 
vasopressin. Both neuropeptides are mainly secreted 
in response to hemodynamic or osmotic changes. Co-
peptin is more stable in blood than vasopressin, which 
is why it has been used in laboratory diagnostics. It 
has been shown that the increased concentration of 
copeptin in blood positively correlates with the risk of 
developing coronary heart disease and the risk of death 
due to CVD [64]. 
Midregional proadrenomedullin  
(MR-proADM)
It is produced by the adrenal medulla, the heart and 
vascular endothelial cells. It is a promising biomarker 
of the risk of developing coronary heart disease and 
heart failure. In addition, MR-proADM may be a prog-
nostic biomarker after STEMI (ST-Elevation Myocardial 
Infarction) [65]. 
Biomarkers of shear stress  
in the vascular endothelium
Shear stress biomarkers include various miRNAs. 
miRNA-143 and miRNA-145 change the phenotype of 
vascular smooth muscle cells to contractile. miRNA-
126-5p limits the proliferation of vascular endothelial 
cells, whereas miRNA-92a enhances the development 
of inflammatory processes in the vascular wall [58].
Biomarkers of blood  
vessel microcalcification
Microcalcification of the atherosclerotic plaque increases 
the risk of its rupture. miRNA-125b is involved in the dif-
ferentiation of vascular smooth muscle cells into osteoblasts 
that build up calcium in the atherosclerotic plaque [58].
Table 1. Characteristics of selected microRNA involved in the development of atherosclerotic process [based on 58]
MicroRNA (miRNA) Role in the atherosclerotic process
miRNA-126 Inhibition of VCAM-1
miRNA-155, -222, -424, -503, -9, -17, -20a, -106a Regulation of monocyte differentiation into macrophages in 
atherosclerotic plaque
miRNA-147, -155, -342-5p Activation of M1 macrophages, increase secretion of  TNF-a 
and IL-6 
miRNA-125a, -146a, -33, -155 Inhibition of lipid accumulation in atherosclerotic plaque
miRNA-15a, -16 Modulation of macrophage apoptosis
miRNA-21, miRNA-34a Production of MMP-9, VSMC proliferation
miRNA-210 Tubulogenesis and stimulation of macrophage migration
miRNA-146a The formation of the Th1 mononuclear phenotype
miRNA-29 Inhibition of elastin expression
miRNA-221/222 Stimulation of cell proliferation or apoptosis
miRNA-365 Stimulation of endothelial cells apoptosis
miRNA-100, -127, -145, -133a, -133b High expression in symptomatic atherosclerotic plaques in 
carotid arteries
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Changes in the structure and function  
of blood vessels with age
The structure and function of blood vessels change with 
age. These changes include a reduction in the number of 
elastic elements, such as collagen and elastin [66]. The 
blood vessels are becoming more rigid, which results 
in an increase in the speed of the pulse wave and its 
amplitude. The reflected pulse wave from the arterioles 
increases the afterload of the left ventricle, which leads 
to increased systolic blood pressure. The increase in 
afterload results in the enlargement of the left ventricle 
and decrease in coronary flow leading to heart failure. 
The lack of return of the pulse wave during diastole 
leads to a decrease DBP (diastolic blood pressure). 
An increase in SBP and a decrease in DBP leads to an 
increase in pulse pressure. The pulse pressure (SBP – 
DBP) increases after 50–60 years due to the structural 
changes described above. A positive correlation was 
found between pulse pressure and cardiovascular risk. 
An increase pulse pressure > 63 mm Hg dramati-
cally increases the risk of CVD. It is worth noting that 
the increase in heart rate with age can be prevented 
through regular physical activity [67, 68]. With age, 
there is a reduction in nitric oxide production while 
increasing the production of endothelin-1. Endothelin-1 
has a strong vasoconstrictive, proinflammatory and 
prooxidative activity. In addition, during the aging of the 
body, the production of proteins and pro-inflammatory 
cytokines, such as CRP, IL-6, IL-8, TNF-a, increases. All 
these changes lead to an increase in the progression of 
atherosclerotic lesions (Fig. 4.) [69, 70].
The influence of statins and PCSK-9  
inhibitors on atherosclerotic plaque
Statins reduce cardiovascular risk by reducing LDL cho-
lesterol and pleiotropic effects. The most effective are the 
so-called strong statins (rosuvastatin, atorvastatin) [71]. 
Pleiotropic properties of statins include anti-inflam-
matory activity (decreased production of CRP, serum 
amyloid A, IL-6, IL-8, ICAM-1), lipid-lowering effect 
(reduction of endogenous cholesterol biosynthesis, 
increase in LDL receptors — apoB100/apoE), anticoagu-
lant (increase in NO production, increase in fibrinolytic 
activity, decrease in ET-1 production) and antioxidant 
activity (reduction of reactive oxygen species produc-
tion, reduction of glutathione reduction, reduction of 
lipoprotein oxidation, reduction of NADPH oxidase 
activation, increased eNOS activity) [72]. Numerous 
studies have demonstrated the beneficial effect of statin 
therapy on reducing the progression of atherosclerosis. 
In the Kumbhani et al. study, it was concluded that sta-
tin therapy reduced the exacerbation of ischemia, the 
need for revascularization, the need for amputation. 
Statins restricted progression of PAD [73]. In addition, 
intensive statin therapy has been shown to reduce 
the volume of atherosclerotic plaque (by 7.69 mm3) 
and increase the lumen of the vessel by 0.81 mm3. 
Rosuvastatin more effectively reduces the volume of 
atherosclerotic plaque compared to atorvastatin [74]. 
Auscher et al. [75] showed that the use of statins leads 
to stabilization of the atherosclerotic plaque, and thus 
reduce the risk of its rupture. 
Proprotein convertase of subtilisin/kexin type 9 
(PCSK-9) was discovered in 2003. PCSK-9 is an inhib-
itor of the LDL lipoprotein receptor (LDL-R). PCSK 
9 binds with LDL-R on the surface of liver cells and 
promotes degradation of LDL(R) in the liver cells by 
the lysozyme pathway and prevents its recycling back 
to the liver cell surface [76]. PCSK-9 inhibitors are hu-
man monoclonal antibodies (evolocumab, alirocumab). 
Phase I and II studies have shown that evolocumab 
reduces LDL levels by 40 to 80%, apolipoprotein B100 
levels by 30–59% and apolipoprotein A by 18–36% 
[77–79]. In the GAUSS2 study, evolocumab showed 
a greater reduction in LDL compared to ezetimibe 
(56.1% versus 36.9%) [79]. The study of Stein et al. 
showed that the use of alicocumab in patients (n = 62) 
with hypercholesterolemia who had an initial LDL 
concentration of 140–170 mg/dl led to a reduction in 
LDL concentration by 29–68% [80]. PCSK 9 inhibitors 
have excellent lipid-lowering properties and beneficial 
effect on CV outcome [76]. According to the FDA 
(Food and Drug Administration), the indications for the 
use of PCSK-9 inhibitors are 1) patients suffering from 
homozygous familial hypercholesterolemia (HOFH) and 
heterozygous familial hypercholesterolemia (HeFH); 
2) non-familial hypercholesterolemia patients who are 
severely statin intolerant (secondary prevention) and 
3) as a research tool [76]. 
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Figure 4. Structural and functional changes of blood vessels 
with age [on based 19, 66–70]. CRP: C-reactive protein; IL-6: 
interleukin 6; IL-8: interleukin 8; TNF-a: tumor necrosis factor 
a; NO: nitric oxide; ET-1: endothelin 1; ROS: reactive oxygen 
species; oxLDL: oxidazed low-density lipoprotein; CVD: car-
diovascular diseases
36
Acta Angiol, 2020, Vol. 26, No. 1
www.journals.viamedica.pl/acta_angiologica
Summary
The pathogenesis of atherosclerosis is very complex. 
Biomarkers of atherosclerotic lesions are often risk 
factors for its occurrence. These are proteins, enzymes, 
microRNAs and others (Fig. 5). There are many modern 
biomarkers that can become routine in the laboratory 
diagnosis of CVD in the future. Modern pharmacothera-
py allows limiting the progression of the atherosclerotic 
process by affecting all its stages — from increasing the 
LDL cholesterol to the atherosclerotic plaque rupture. 
Further research will provide further information on the 
pathogenesis of atherosclerosis, and as a result, new 
risk factors and biomarkers will be recognized.
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